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Abstract
Background: Hereditary angioedema types I and II are caused by a functional
deficiency of C1 inhibitor (C1-INH), leading to overproduction of bradykinin.
The current functional diagnostic assays employ inhibition of activated C1s; how-
ever, an alternative, more physiologic method is desirable.
Methods: ELISAs were developed using biotinylated activated factor XII (factor
XIIa) or biotinylated kallikrein bound to avidin-coated plates. Incubation with
plasma was followed by detection of bound C1-INH.
Results: After standard curves were developed for quantification of C1-INH,
serial dilutions of normal plasma were employed to validate the ability to detect
known concentration of C1-INH in the plasma as a percent of normal. Heredi-
tary angioedema (HAE) types I and II were then tested. The level of functional
C1-INH in all HAE types I and II plasma tested was less than 40% of our nor-
mal control. This was evident regardless of whether we measured factor XIIa–C1-
INH or kallikrein–C1-INH complexes, and the two assays were in close agree-
ment. By contrast, testing the same samples utilizing the commercial method
(complex ELISA, Quidel Corp.) revealed the levels of C1-INH between 0 and
57% of normal (mean, 38%), and 42 samples were considered equivocal (four
controls and 38 patients).
Conclusions: Diagnosis of HAE types I and II can be ascertained by inhibition of
enzymes of the bradykinin-forming cascade, namely factor XIIa and kallikrein.
Either method yields functional C1-INH levels in patients with HAE (types I and
II) that are clearly abnormal with less variance or uncertainty than the commer-
cial method.
Hereditary angioedema (HAE), types I and II, is an autoso-
mal dominant disorder characterized by recurrent swelling in
the extremities, face, gastrointestinal tract, or upper airways
(1). Attacks last 2–5 days, and if not treated appropriately,
swelling of the larynx, in particular, can be fatal. Since this is
a rare disorder (affecting 1 in 20 000 to 1 in 50 000 people)
with a variable presentation, the diagnosis may be missed.
hereditary angioedema is typically caused by a heterozygous
mutation in the C1 inhibitor (C1-INH) gene, which results in
either reduced protein levels (type I HAE, 85% of cases) or
reduced function (type II HAE, 15%) (2). To distinguish
these two subtypes, the diagnosis of HAE is made by mea-
suring both the antigenic and functional levels of C1-INH. In
type I HAE, C1-INH protein level is low and the functional
level is proportionately low, whereas in type II HAE, the
protein level is normal, or even elevated, but the functional
level is low. Thus, a functional assay is requisite, not only to
confirm the diagnosis of HAE, but also type II disease can-
not be diagnosed without it. Diagnosing HAE is critical as
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the mortality of untreated disease is around 30% due to
asphyxiation (3–5).
C1 INH is a serine protease enzyme that inhibits activated
proteins of the complement, coagulation, and kinin-forming
cascades. The commercial assays used to assess C1-INH
functional levels measure the inhibition of C1s of the comple-
ment cascade by C1-INH, utilizing either a chromogenic
assay or a complex ELISA method. The chromogenic assay
is generally considered preferable (6), but both methods have
limitations. The chromogenic assay is more likely to have an
occasional false positive while the complex ELISA has a neg-
ative predictive value of only 62% (6).
A theoretical limitation of both methods is that the assays
measure the activity of C1-INH on an enzyme of the
complement cascade and not the bradykinin-forming cascade.
It is the inability of C1-INH to inhibit activated factor XII
(7) and plasma kallikrein (8) that leads to overproduction of
bradykinin, and the latter occurrence is the cause of
angioedema in HAE (9). In support of this, a dysfunctional
C1-INH has been described, which has normal activity on
the kinin-forming cascade; hence, no angioedema occurs, but
it fails to inhibit C1s so that C1 is abnormally active and C4
is depleted (10, 11). If the reverse were to occur, that is, a
mutated inhibitor that inhibits activated C1s but not kallik-
rein or factor XIIa, it could not be diagnosed with the cur-
rent methodology. Thus, an assay with physiologic relevance
would be a major advance over the current methods. We
report herein two novel assays for functional C1-INH
employing ELISA methodology based on either inhibition of
activated factor XII or plasma kallikrein to diagnose HAE
types I and II.
Materials and methods
Patients and sample collection
The diagnosis of HAE was confirmed by clinical presenta-
tion, low C1-INH protein, and/or functional level (1, 2) using
the commercial assay performed at the site of origin of the
samples. Citrated plasma from 87 patients (77 type I and 10
type II) with HAE and 47 healthy controls was separated by
centrifugation of freshly collected blood at 1200 g for 10 min
at 4°C. All samples were immediately aliquoted and stored at
80°C. Samples were handled similarly at all participating
sites (Odense, Denmark; Budapest, Hungary) and shipped
overnight on dry ice. The protocol was approved by the Eth-
ics Committee and Data Protection Agency at both partici-
pating sites.
Purified human factor XIIa and kallikrein were obtained
from Enzyme Research Laboratories (South Bend, IN, USA),
the biotinylation reagent was obtained from Thermo Scientific
(Rockford, IL, USA), and all other reagents were obtained
from Sigma Chemical Company (St. Louis, MO, USA).
Biotinylation of proteins
The proteins were biotinylated according to the manufac-
turer’s recommendations. Briefly, 1 mg of protein (kallikrein
or factor XIIa) was dissolved in 0.5 ml of phosphate-buffered
saline (PBS). Twenty-seven microliters of freshly prepared
10 mM Sulfo-NHS-LC-biotin was added to the protein solu-
tion and incubated on ice for 2 h. Excess nonreacted and
hydrolyzed biotin was removed using a spin-desalting column.
The labeling of the proteins was confirmed by ELISA, and the
protein concentration was determined by Bradford assay (12).
ELISA to measure C1-INH protein level in plasma
Immulon 2HB plates were coated with 5 lg/ml polyclonal
antibody to C1-INH. After blocking with 1% BSA in PBS,
samples and standards were added and incubated at room
temperature for 1 h. Bound C1-INH was probed with
alkaline phosphatase-conjugated monoclonal antibody to
C1-INH followed by color development using 5-bromo-4-
chloroindolyl phosphate/nitroblue tetrazolium (BCIP/NBT).
Quantification of functional C1-INH in plasma based on
inhibition of kallikrein and factor XIIa
Immulon 2HB plates were coated with 5 lg/ml avidin in
coating buffer (100 ll) overnight at 4°C. Plates were washed
three times using PBS-Tween (200 ll/each). Subsequently,
200 ll 1% BSA in PBS was added to block the unused sites.
The plates were incubated at 37°C for 1 h and were washed
three times using PBS-Tween (200 ll/each). Samples or stan-
dards were added to the plates along with biotinylated pro-
tein (25 ll standards or samples, 25 ll biotinylated factor
XII or biotinylated kallikrein (1 lg/ml), and 50 ll binding
buffer), were mixed, and incubated at 37°C for 1 h. After
incubation, plates were washed three times using PBS-Tween
(200 ll/each). A polyclonal antibody to C1-INH was added,
followed by incubation at room temperature for 1 h. The
wells were washed with PBS-Tween three times. Alkaline
phosphatase-conjugated secondary antibody was added, and
the samples were incubated at room temperature for 1 h fol-
lowed by color development using phosphatase substrate
BCIP/NBT. The OD at 450 nm was read, and calculations
were performed using the standard curve. The method is
summarized step by step in Fig. 1.
Quantification of functional ELISA based on inhibition of
C1s
ELISA kit was purchased from Quidel Corporation to mea-
sure the amount of functional C1-INH. This assay is based
on the ability of plasma C1-INH to inhibit the first compo-
nent of the complement cascade: activated C1s (utilizing a
complex ELISA assay). The assay was performed according
to the manufacturer’s protocol.
Results
Diagnosis of HAE by inhibition of C1s
We tested C1 INH function of 46 samples from normal con-
trols and 87 samples from patients with either type I or type II
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HAE using a commercial assay (complex ELISA, Fig. 2A).
According to the assay interpretation, ‘normal’ is 68–100%
C1-INH while ‘abnormal’ is below 67%. The instructions indi-
cate that samples between 41% and 67% are to be repeated,
because they are considered equivocal, but if the repeat value
is within this range, it is reported as abnormal. Standards were
supplied as a percentage of normal, that is, standards were
0%, 23%, 44%, 66%, and 88%, and unknowns are read off
the curve. The normal subjects varied between 62% and 100%
while the HAE samples varied between 0 and 57%. The mean
and standard deviation for HAE samples was 38  13%.
There were 42 samples that were considered equivocal (four
controls and 38 patients) and needed repeat measurements.
The repeat measurements revealed normal levels in controls
and were abnormal in the patients with HAE.
Diagnosis of HAE by inhibition of kallikrein or factor XIIa
The results employing inhibition of plasma kallikrein or
inhibition of factor XIIa expressed as percentage of control
(pooled normal plasma) are shown in Fig 2B and C, respec-
tively, where normal controls are compared to samples
obtained from the same patients with types I and II HAE
assayed above. The mean and standard deviation for factor
XIIa–C1-INH were as follows: normal, 90  12%; types I
and II HAE, 16  8%. The ‘P’ value comparing types I and
Figure 1 A diagrammatic representation of the ELISA method to detect functional C1-INH in plasma.
A
B C
Figure 2 Functional ELISA based on inhibition of complement C1s
(A), kallikrein (B), or factor XIIa (C): ELISAs were performed as
described in ‘Materials and methods’. Results (mean  SD) are
expressed as percentage of controls.
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II HAE to normal controls was <0.0001. The results obtained
assaying for kallikrein–C1-INH complexes were strikingly
similar with no overlap between groups (normal, 89  14%;
types I and II HAE, 17  9%; ‘P’ value comparing types I
and II HAE to normal controls: <0.0001). There were no
false positives or false negatives employing this methodology.
These assays were performed in duplicate.
Discussion
Our results show that the assays for factor XIIa–C1-INH
complex formation or for kallikrein–C1-INH complex
formation correctly identified 100% of the patients with types
I and II HAE with low functional C1-INH as compared to
normal controls (Figs 1 and 2). Our rationale was that it
would be preferable to develop an assay that measures the
activity of C1-INH on an enzyme that is requisite for brady-
kinin formation. These would therefore employ one of the
activated forms of factor XII (factor XIIa or factor XIIf) or
plasma kallikrein. We assumed that inhibition of factor XIIa
would be simpler since it has no other significant inhibitor in
plasma while plasma kallikrein is also inhibited by a2 macro-
globulin. Nevertheless, both methods work well as we detect
only that fraction of kallikrein (~60%), which is inhibited by
C1-INH (13).
Our approach was to biotinylate the active enzyme, bind it
to an avidin-coated plate, incubate with plasma (normal for
a control, putative HAE plasma as the unknowns), and mea-
sure the enzyme–C1-INH complex. We employed alkaline
phosphatase-labeled antibody to C1-INH for the detection of
bound C1-INH. For the quantification of C1-INH, a stan-
dard curve was made by substituting known quantities of
C1-INH in buffer, in place of plasma. This method is similar
to the complex ELISA method currently employed for inhibi-
tion of C1s by C1-INH (14). Furthermore, if other types of
angioedema (HAE with normal C1-INH function, for exam-
ple) had a mutant C1-INH that inhibits activated factor XII
or kallikrein but not C1s, we would detect the abnormality
using this method, whereas the diagnosis would be missed
employing either of the currently available assays. Our meth-
ods have the possibility to supplant the current commercial
methods for the diagnosis of types I and II HAE as either
one appears to be more sensitive for the detection of dysfunc-
tional C1-INH than does the inhibition of C1s, and/or could
also be used to evaluate patients where an equivocal result is
obtained employing current methodology. The assay is iden-
tical in complexity to any of the commercial assays and can
be performed in 3–4 h if it is made available commercially.
The diagnosis of HAE can be made with these assays alone,
although a C1-INH protein determination is needed to distin-
guish type II HAE from type I HAE. It can also shed further
light on type III HAE, that is, HAE with ‘normal’ C1 inhibi-
tor and readily distinguish it from type I or II HAE. About
5% of patients with type I or II HAE have a normal C4 level
when asymptomatic (2), even though functional C1-INH is
abnormal; during an attack of swelling, C4 approaches zero
and levels of C2 decline (15). Thus, in patients with type II
HAE, the diagnosis can be dependent solely on a functional
assay unless a mutation in C1-INH protein or mRNA is
defined. Our method(s) would be particularly useful in this
circumstance. In conclusion, the diagnosis of HAE types I
and II can be ascertained by inhibition of enzymes of the
bradykinin-forming cascade so that the diagnosis is made by
functional assessment that is directly related to the abnormal-
ity leading to angioedema.
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